|
|
Sunday, June 5 |
|
||||
|
|
|
|
|
|
||
|
|
6:00 PM |
|
Conference Registration |
|||
|
|
|
|
|
|||
|
|
8:00 PM |
|
Welcome Reception/Dinner |
|||
|
|
|
|
|
|||
|
|
Monday, June 6 |
|
||||
|
|
|
|
|
|
||
|
|
7:30 AM |
|
Breakfast |
|
||
|
|
|
|
|
|
||
|
|
8:30 AM |
|
Welcome and Opening Remarks |
|
||
|
|
|
|
|
|
||
|
|
Session I |
|
Tumor Immunology and Immunotherapy I: Basic mechanisms & preclinical research Chair: Costas Koumenis |
|
||
|
|
8:35 AM |
1 |
Reprogramming the immunologic microenvironment through radiation and axl targeting Todd A Aguilera, Marjan R Rafat, Laura Castellini, Mihalis S Kariolis, Rie von Ebyen, Edward E Graves, and Amato J Giaccia |
|
||
|
|
9:00 AM |
2 |
Antiviral signaling regulates response to conventional cancer therapy and immune checkpoint blockade Andy Minn |
|
||
|
|
9:25 AM |
3 |
Alternative splicing as a mechanism of resistance to immunotherapy Andrei Thomas-Tikhonenko |
|
||
|
|
9:50 AM |
4 |
Mechanisms of immunosuppression within the tumor microenvironment Serge Fuchs |
|
||
|
|
|
|
|
|
||
|
|
10:15 AM |
|
Coffee Break/Poster Viewing |
|
||
|
|
|
|
|
|
||
|
|
Session II |
|
Tumor Immunology and Immunotherapy II: Clinical research and practice Chair: Amato Giaccia |
|
||
|
|
10:50 AM |
5 |
Ablative radiation therapy and immune checkpoint inhibition: Where do we go from here? Stephen Hahn |
|
||
|
|
11:15 AM |
6 |
RADVAXTM: A stratified phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic cancers Amit Maity |
|
||
|
|
11:40 AM |
7 |
Radiation and Immune Modulation: Where are we now and what's next? Ramesh Rengan |
|
||
|
|
12:05 PM |
8 |
Precision medicine in oncology: The MD Anderson Cancer Center Initiative Apostolia-Maria Tsimberidou |
|
||
|
|
Session III |
|
Imaging of the tumor and its microenvironment Chair: Michael Hay |
|
||
|
|
|
|
|
|
||
|
|
12:30 PM |
9 |
Deep tissue optoacoustic assessment of tumor microenvironment Vasilis Ntziachristos |
|
||
|
|
12:55 PM |
10 |
Imaging the tumour microenvironment using clinically applicable approaches: pros and cons Michael Horsman, Ane Iversen, and Morten Busk |
|
||
|
|
1:20 PM |
11 |
A novel PARP inhibitor PET tracer for ovarian carcinoma Lilie Lin |
|
||
|
|
1:45 PM |
12 |
Multimodality imaging of tumour vasculature and the effects of therapy Sean Johnson, Ollie Ogunlade, Paul Beard, Mark Lythgoe, Simon Walker-Samuel, and Barbara R Pedley |
|
||
|
|
1:55 PM |
13 |
Tumor microenvironment modulates the anticancer benefits of esomeprazole Silvana Papagerakis, Eleftheria Mavridou, Ngya Nguyen, Li Zhengl, and Petros Papagerakis |
|
||
|
|
|
|
|
|
||
|
|
2:10 PM |
|
Lunch/Informal Discussions |
|
||
|
|
|
|
|
|
||
|
|
7:30 PM |
|
Dinner/Informal Discussions at a local Greek Restaurant Buses depart from the hotel lobby at 7:30 PM |
|
||
|
|
|
|
|
|
||
|
|
Tuesday, June 7 |
|
||||
|
|
|
|
|
|
||
|
|
7:30 AM |
|
Breakfast |
|
||
|
|
|
|
|
|
||
|
|
Session IV |
|
Tumor hypoxia I: effects on gene expression, cell fate Chair: Ester Hammond |
|
||
|
|
8:30 AM |
14 |
Assessment of tumor hypoxia: Facts and fallacies Peter Vaupel and Arnulf Mayer |
|
||
|
|
8:55 AM |
15 |
Hypoxia-induced replication stress: causes and consequences Ester M Hammond |
|
||
|
|
9:20 AM |
16 |
Phosphorylation-dependent interactions mediate distinct nuclear and cytoplasmic/non-transcriptional functions of hypoxia-inducible factor-1α Ilias Mylonis, Maria Kourti, and George Simos |
|
||
|
|
9:45 AM |
17 |
Hypoxia-regulated non-coding RNA species Kevin Bennewith |
|
||
|
|
10:10 AM |
18 |
HIF-dependent repression of CPT1A drives the clear-cell phenotype of clear cell renal cell cCarcinoma Scott Welford, Weinan Du, Charles Hoppel, Laura Herrero, and Dolors Serra |
|
||
|
|
10:35 AM |
19 |
Tumor cell fate regulation by the hypoxic tumor Microenvironment Qun Lin, Hoon Kim, and Zhong Yun |
|
||
|
|
10:45 AM |
20 |
WSB-1 regulates the metastatic potential of ER- and PR-negative breast cancer Flore-Anne Poujade, Lisa Eigleman, Aarren Mannion, Andrew Theodosi, Christopher Cawthorne, and Isabel Pires |
|
||
|
|
|
|
|
|
||
|
|
10:55 AM |
|
Coffee Break/Poster Viewing |
|
||
|
|
|
|
|
|
||
|
|
Session V |
|
Tumor hypoxia II: impact on tumor metabolism & tumor targeting Chair: Barbara Pedley |
|
||
|
|
11:30 AM |
21 |
Heterogenic hypoxia induced populations defined by CAIX expression display metabolic symbiosis Adrian Harris, Kate Feldinger, Ioanna Ledaki, and Simon Wigfield |
|
||
|
|
11:55 AM |
22 |
Regulation of intermediate metabolism by the tumor microenvironment Tereza Golias, Ioanna Papandreou, Megan Miller, Wendi O’Neill, Ramon Sun, and Nicholas Denko |
|
||
|
|
12:20 PM |
23 |
Fumarate hydratase (FH)-dependent metabolic adaptation to hypoxia Marianne Koritzinsky |
|
||
|
|
12:45 PM |
24 |
Lipid droplet proteins can modulate cellular metabolism and malignant progression Ioanna Papandreou |
|
||
|
|
1:10 PM |
25 |
Dual targeting of hypoxia and low extracellular pH in the tumour microenvironment Michael Hay, Hong Shin, Way-Wua Wong, Benjamin Dickson, Kevin Hicks, and William Wilson |
|
||
|
|
1:35 PM |
26 |
Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling Jing Chen |
|
||
|
|
2:00 PM |
27 |
Hypoxia and glucose/energy depletion: regulators of the tumour vascular disrupting actions of combretastatin A-4 phosphate Chryso Kanthou, Toby Holmes, Andrew Brown, and Gillian Tozer |
|
||
|
|
|
|
|
|
||
|
|
2:10 PM |
|
Lunch/Informal Discussions |
|
||
|
|
|
|
|
|
||
|
|
7:30 PM |
|
Dinner/Informal Discussions at a local Greek Restaurant Buses depart from the hotel lobby at 7:30 PM |
|
||
|
|
|
|
|
|
||
|
|
Wednesday, June 8 |
|
||||
|
|
|
|
|
|
||
|
|
7:30 AM |
|
Breakfast
|
|
||
|
|
Session VI |
|
Tumor-Stroma interactions and impact on angiogenesis/vasculogenesis Chair: Zhong Yun |
|
||
|
|
8:30 AM |
28 |
Heterogeneity of tumor stroma: Implications for stroma-targeted therapies Ellen Puré |
|
||
|
|
8:55 AM |
29 |
The biology and function of exosomes Raghu Kalluri |
|
||
|
|
9:20 AM |
30 |
Intertwined Functional Regulation of Angiogenesis, Invasion and Immunity in Cancer Gabriele Bergers |
|
||
|
|
9:45 AM |
31 |
MET/AXL upregulation as a mechanism of resistance to antiangiogenic therapy Eric Jonash |
|
||
|
|
10:10 AM |
32 |
The role of endothelial-derived Thrombospondin-1 in tumor growth and chemotherapeutic resistance Dong Ha Bhang, Joo-Hyeon Lee, Bang-Jin Kim, Kwan-Hyuck Baek, Keri Schadler, Carla Kim, and Sandra Ryeom |
|
||
|
|
10:35 AM |
33 |
Transformation of tumor endothelial cells to mesenchymal stem cell-like cells Menggui Huang and Yi Fan |
|
||
|
|
11:00 AM |
34 |
Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment Hongyu Tian |
|
||
|
|
|
|
|
|
||
|
|
11:10 AM |
|
Coffee Break/Poster Viewing |
|
||
|
|
|
|
|
|
||
|
|
Session VII |
|
Stress resistance & cancer I: Targeting organelle-specific stress responses Chair: Bradly Wouters |
|
||
|
|
11:50 AM |
35 |
Autophagy Prevents Fatal Nucleotide Pool Depletion in Ras-driven Cancer Cells Eileen White |
|
||
|
|
12:15 PM |
36 |
Targeting the lysosome in cancer Ravi Amaravadi |
|
||
|
|
12:40 PM |
37 |
Ubiquitin ligases in melanoma development and resistance to therapy Hyungsoo Kim, Yan Li, Ali Khateb, Yongmei Feng, and Ze’ev Ronai |
|
||
|
|
1:05 PM |
38 |
Golgi stress and secretory stress signaling Jan Reiling |
|
||
|
|
1:30 PM |
39 |
Downregulation of carbonic anhydrase IX impairs ECM degradation and affects actin regulatory proteins during invadopodia formation Michaela Debreova, Lucia Csaderova, Olga Sedlakova, Silvia Pastorekova, and Eliska Svastova |
|
||
|
|
1:40 PM |
40 |
Matrix Metalloproteinase-2 Modulates Inflammation And Melanoma Progression Via TLR-2 Mansi Saxena, Luciana Muniz-Bongers, and Nina Bhardwaj |
|
||
|
|
1:50 PM |
41 |
Novel multi-faceted brain metastasis therapy Manuel Sarmiento Soto, James Larkin, Kleopatra Andreou, and Nicola Sibson |
|
||
|
|
|
|
|
|
||
|
|
2:00 PM |
|
Lunch/Informal Discussions |
|
||
|
|
|
|
|
|
||
|
|
3:30 PM |
|
City Tour Buses depart from hotel lobby at 3:30 PM |
|
||
|
|
|
|
|
|
||
|
|
7:30 PM |
|
Dinner/Informal Discussions at a local Greek Restaurant Please note buses do not pick-up at the hotel prior to dinner. Dinner proceeds right after the tour. |
|
||
|
|
|
|
|
|
||
|
|
Thursday, June 9 |
|
||||
|
|
|
|
|
|
||
|
|
7:30 AM |
|
Breakfast |
|
||
|
|
|
|
|
|
||
|
|
Session VIII |
Stress resistance & cancer II: ER stress and the Unfolded Protein Response Chair: Marianne Koritzinsky |
|
|||
|
|
8:30 AM |
42 |
Oncogenic Stress overrides the circadian clock through UPR-dependent micro-RNA regulation Yiwen Bu, Chi Van Dang, Costas Koumenis, Serge Fuchs, and Alan Diehl |
|
||
|
|
8:55 AM |
43 |
The C/EBPdelta transcription factor is a signaling hub for promotion of cancer cell stemness and is regulated by the unfolded protein response Kuppusamy Balamurugan, Namratha Sheshadri, Shikha Sharan, and Esta Sterneck |
|
||
|
|
9:20 AM |
44 |
Genome-wide CRISPR screens identifies novel modulators of cell fate during ER stress Constantinos Koumenis, Souvik Dey, and Lauren Brady |
|
||
|
|
9:45 AM |
45 |
IRE1-dependent immune surveillance in glioblastoma Eric Chevet |
|
||
|
|
10:10 AM |
46 |
The unfolded protein response promotes tolerance to hypoxia through maintenance of mitochondrial and ER homeostasis through ULK1 Dan Cojocari, Ravi Vellanki, Marianne Koritzinsky, and Bradly Wouters |
|
||
|
|
10:35 AM |
47 |
PERK Activation Promotes Medulloblastoma Tumorigenesis by Attenuating Pre-malignant Granule Cell Precursor Apoptosis Wensheng Lin |
|
||
|
|
|
|
|
|
||
|
|
10:45 AM |
|
Coffee Break/Poster Viewing |
|
||
|
|
|
|
|
|
||
|
|
Session IX |
|
Stress resistance & cancer III: Oncogenic stress and signaling Chair: Esta Sterneck |
|
||
|
|
11:30 AM |
48 |
Translation initiation factor eIF2α serine 51 phosphorylation couples with the mammalian target of rapamycin (mTOR) to determine cell fate and tumorigenesis under stress Antonis Koromilas |
|
||
|
|
11:55 AM |
49 |
The potential of MK2 inhibition in cancer therapy Lenka Munoz |
|
||
|
|
12:20 PM |
50 |
Inhibition of EGFR palmitoylation creates EGFR signaling dependency Eric Witze, Kristin Runkle, Akriti Kharbanda, Xing-Jun Cao, and Ewa Stypulkowski |
|
||
|
|
12:45 PM |
51 |
Atr inhibition induces DNA damage and apoptosis in medulloblastoma and attenuates tumorigenesis Patrick Lang, Jaclyn Wu, Jing Gao, Duhyeong Hwang, Alexander Kabanov, Marina Sokolsky-Papkov, and Timothy Gershon |
|
||
|
|
12:55 PM |
52 |
Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas Yari Ciribilli, Prashant Singh, Reinhard Spanel, Alberto Inga, and Jürgen Borlak |
|
||
|
|
1:05 PM |
|
Crosstalk between p53 family and hypoxia inducible factor in cancer Ivano Amelio and Gerry Melino
|
|
||
|
|
|
|
|
|
||
|
|
Session X |
|
Meet the experts Chair: Ravi Amaravadi |
|
||
|
|
1:15 PM |
52 |
P01 -Multidisciplinary Coordinated Research Program at the National Cancer Institute: Current Status and Future Trends Konstantin Salnikow |
|
||
|
|
1:40 PM |
53 |
Getting published in the Nature journals: an Editor’s perspective Alexia Zaromytidou |
|
||
|
|
|
|
|
|
||
|
|
2:05 PM |
|
Closing Remarks |
|
||
|
|
|
|
|
|
||
|
|
2:10 PM |
|
Lunch/Informal Discussions |
|
||
|
|
|
|
|
|
||
|
|
8:00 PM |
|
Farewell Dinner |
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
Friday, June 10 |
|
||||
|
|
|
|
|
|
||
|
7:30 AM |
|
Breakfast |
||||
|
|
|
|
|
|
||
|
9:00 AM |
|
Departure
|
||||
|
|
POSTERS |
|
|
54 |
A cyclic peptide derived of urokinase receptor generates a potent inhibitor of the growth and invasion in a mouse model of chondrosarcoma Domenica Rea and Claudio Arra |
|
|
55 |
A metabolomic discovery approach for identification of metabolic changes associated with MET inhibition and DNA damaging agents in MET-addicted and non-MET-addicted cellular systems Michaela Poliakova, Nicola Zamboni, Aebersold Daniel, Michaela Medova, and Yitzhak Zimmer |
|
|
56 |
A novel role for the complement cascade in the resistance of oesophageal adenocarcinoma to chemoradiation therapy Niamh Lynam-Lennon, Danica Lavin, Becky Bibby, Stephen Maher, John Reynolds, and Jacintha O'Sullivan |
|
|
57 |
Aberrant actin stress fibre formation and extracellular milieu modifications prevent local invasion and metastasis formation in response to novel estrone analogues in breast- and cervical cancer cells Anne Theron, Laurence Lafanechère, Renaud Prudent, and Annie Joubert |
|
|
58 |
Association of ascorbate and hypoxia inducible factor-1 in samples from breast cancer patients Elizabeth Campbell, Gabi Dachs, Helen Morrin, Bridget Robinson, and Margreet Vissers |
|
|
59 |
Cancer therapy by promoting differentiation of cancer stem cells Daniela Pankova |
|
|
60 |
Crosstalk between the mutational landscape of an innate immune system pathway and tumor hypoxia Monica Olcina, Nikolas Balanis, Ryan Kim, Edward LaGory, AJ Venkatakrishnan, David Hewings, Thomas Graeber, and Amato Giaccia |
|
|
61 |
Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer Sabrina Bimonte, Antonio Barbieri, Giuseppe Palma, Antonio Luciano, Claudio Arra, and Francesco Izzo |
|
|
62 |
Development of immunomonitoring assays for dendritic cell-based lung cancer immunotherapy Ondřej Palata, Lenka Sadílková, Naďa Hradilová, Irena Vančurová, Dagmar Myšíková, Hana Mrázková, Robert Lischke, Radek Špíšek, and Irena Adkins |
|
|
63 |
Distinct immune status in patients with adenocarcinoma and squamous cell carcinoma: implication for immunotherapy of non-small cell lung cancer Nada Hradilova, Ondrej Palata, Lenka Sadilkova, Dagmar Mysikova, Hana Mrazkova, Robert Lischke, Radek- Spisek, and Irena Adkins |
|
|
64 |
Epigenetic determinants of immunotherapy response Navneet Singh, Vishnu Modur, Vakul Mohanty, Gang Huang, and Kakajan Komurov |
|
|
65 |
ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells Iman Khan, Byong Yoo, Olivier Masson, Sylvain Baron, Dale Corkery, Graham Dellaire, Laura Attardi, and Kirill Rosen |
|
|
66 |
Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines Kamila Kloudova, Simona Partlova, Anna Fialova, Radek Spisek, and Tomas Brtnicky |
|
|
67 |
GCN2 and cell-cycle progression Cathrine Bøe, Tine Håland, Erik Boye, Randi Syljuåsen, and Beata Grallert |
|
|
68 |
Genetic alterations of the siah-1 gene in hepatocellular carcinomas Neung Hwa Park |
|
|
69 |
HGF-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes Deborah Morena, Nicola Maestro, Francesca Bersani, Paolo Forni, Marcello Lingua, Valentina Foglizzo, Petar Šćepanović, Silvia Miretti, Alessandro Morotti, Jack Shern, Javed Khan, Ugo Ala, Paolo Provero, Valentina Sala, Tiziana Crepaldi, Patrizia Gasparini, Michela Casanova, Andrea Ferrari, Gabriella Sozzi, Roberto Chiarle, Carola Ponzetto, and Riccardo Taulli |
|
|
70 |
Human CYP1B1 activates uPAR signaling pathway to promote cancer progression and metastasis in human breast cancer cells Young-Jin Chun |
|
|
71 |
Hypoxia and macrophages modulate cancer cell responses to chemotherapy Carine Michiels, Francois Clement, Marie Genin, Celine Tellier, Olivier Feron, and Martine Raes |
|
|
72 |
Hypoxia in the tumor microenvironment: A formidable saboteur of the anti-tumor immune response Tsolère Arakelian, Takouhie Mgrditchian, Guy Berchem, Salem Chouaib, and Bassam Janji |
|
|
73 |
Identification of novel PGE2 Receptor Antagonists that modulate angiogenesis and inflammation in Oesophageal Adenocarcinoma Anne-Marie Byrne, Mary-Clare Cathcart, Michelle Lowry, Breandan Kennedy, Nicholas Pullen, James Phelan, Niamh Clarke, John Reynolds, Jacintha Sullivan, and Graham Pidgeon |
|
|
74 |
IGF-II mRNA-Binding Protein 3 (IMP3) contributes to glioma stem-like cell maintenance and contributes to chemo-radio resistance by increasing translation of RELA Shruti Bhargava, Vikas Patil, Abhirami Visvanathan, Anuj Kumar, Shwetha Shivayogi, Alangar Hegde, Bangalore Chandramouli, Arimappamagan Arivazhagan, Saumitra Das, Vani Santosh, and Kumaravel Somasundaram |
|
|
75 |
IL-6 effects on expression cell surface molecules on K-562 cells Vladimir Jurisic and Tatjana Srdic-Rajic |
|
|
76 |
Inactivating mechanism of ATBF1 gene in hepatocellular carcinomas Neung Hwa Park |
|
|
77 |
Influence of tumor VEGF isoform expresson on response to a VEGF pathway inhibitor ± radiotherapy Debayan Mukherjee, William English, Sarah-Jane Lunt, Matthew Fisher, Karina Bingham, Khairul Mohd Khatib, Chryso Kanthou, and Gillian Tozer |
|
|
78 |
Inhibition of Flightless 1 reduces tumor growth and spread in a mouse colon cancer model Noraina Zakuan, Dodie Pouniotis, Jessica Jackson, Zlatco Kopecki, Allison Cowin, and Ian Darby |
|
|
79 |
Investigating the role of ATG4B in PDAC growth and survival Paalini Sathiyaseelan, Steve Kalloger, Daniel Renouf, David Schaeffer, Christopher Hughes, Gregg Morin, and Sharon Gorski |
|
|
80 |
Involvement of MET signaling in the HIF-1α pathway Astrid Glück, Michaela Medová, Eleonora Orlando, Dominic Leiser, Daniel Aebersold, and Yitzhak Zimmer |
|
|
81 |
Is there a role for ascorbate in regulating hypoxia factors in renal cell carcinoma? Christina Wohlrab, Elisabeth Phillips, Helen Morrin, Margreet Vissers, Bridget Robinson, and Gabi Dachs |
|
|
82 |
Ketogenic Diet is a potential adjuvant therapy for Neuroblastoma Sepideh Aminzadeh-Gohari, Rene Feichtinger, Silvia Vidali, Felix Locker, Tricia Rutherford, Maura O'Donnel, Andrea Stöger-Kleiber, Johannes Mayr, Wolfgang Sperl, and Barbara Kofler |
|
|
83 |
Magnetic nanoparticles with plasmid DNA encoding shRNA against Mcam for melanoma treatment Lara Prosen, Samo Hudoklin, Gregor Sersa, Monika Stimac, Ursa Lampreht Tratar, Maja Ota, Janez Scancar, Rok Romih, and Maja Cemazar |
|
|
84 |
Manipulating the tumour microenvironment using physiological or pharmacological doses of ascorbate Gabi Dachs, Elizabeth Campbell, Bridget Robinson, and Margreet Vissers |
|
|
85 |
Microfluidic anticancer drug screening with in vivo grown cancer xenografts Bo Young Jung, Song Cheol Kim, and Chang Mo Hwang |
|
|
86 |
MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma via altered intracellular drug trafficking and localisation Stephen Maher, Hannah Moody, and Michael Lind |
|
|
87 |
Modulation of tumor microenvironment properties by manipulation with DNA damage response pathway Oleg Demidov, Anastasia Goloudina, Frédéric Lirussi, Bogdan Grigorash, Carmen Garrido, and Burhan Uyanik |
|
|
88 |
New topoisomerase inhibitor for breast and pancreas cancer Palma Giuseppe, Mariconda Annaluisa, Rea Domenica, Vitale Del Vecchio, Barbieri Antonio, Michela Falco, Agostino Casillo, Domenico Iacopetta, Maria Stefania Sinicropi, Longo Pasquale, Arra Claudio, and Saturnino Carmela |
|
|
89 |
Novel small molecule inhibitors of 5-lipoxygenase are potential therapeutic targets in obesity-driven oesophageal adenocarcinoma Zivile Useckaite, Emma Allott, Helen Sheridan , David Maloney, John Reynolds, and Graham Pidgeon |
|
|
90 |
Predictive value of genetically engineered endogenous mouse models in preclinical therapeutic studies Aayush Gupta, Evdokia Kalideris Kalideris, Marija Trajkovic-Arsic, Rickmer Braren, and Jens Siveke |
|
|
91 |
Reprogramming the transcriptional response to hypoxia Ishna Mistry and Ali Tavassoli |
|
|
92 |
Ribonucleotide reductase favours the RRM2B subunit to maintain DNA replication in hypoxia Iosifina Foskolou, Christian Jorgensen, Katarzyna Leszczynska, Monica Olcina, Vincenzo D’Angiolella, William Myers, Carmen Domene, Emily Flashman, and Ester Hammond |
|
|
93 |
Skin based gene delivery for tumor treatment Spela Kos, Maja Cemazar, Tanja Blagus, Urska Kamensek, Simona Kranjc, and Gregor Sersa |
|
|
94 |
Strain analysis in the assessment of mouse model of cardiotoxicity by chemotherapy: sample for preclinical research Domenica Rea and Claudio Arra |
|
|
95 |
Synthesis and biological evaluation of a noval anticancer drug delivery system: Poly (L-γ-glutamyl- L-Carbocisteine)-Paclitaxel Nanoconjugate Yiting Wang, Jing Wang, Lei Yu, Hui Peng, and Jianzhong Zhu |
|
|
96 |
Synthesis, Characeration and biological evaluation of a nano carbon quantum Lei Yu, Jing Wang, Yiting Wang, Hui Peng, and Jianzhong Zhu |
|
|
97 |
The clinicopathological significance of monocarboxylate transporters (MCTs) and CD147 in germ cell tumors Eduardo da Silva, Flavio Cárcano, Fátima Baltazar, Filipa Morais-Santos, Luiz Lopes, Cristovam Scapulatempo-Neto, and CélinePinheiro |
|
|
98 |
The role of ceramide galactosyltransferase (UGT8) and galactosylceramide (GalCer) in cellular stress response and multidrug-resistance of breast cancer cells Bartlomiej Kocbach, Ida Szmigiel, Jaroslaw Suchanski, Pawel Pasikowski, Piotr Dziegiel, and Maciej Ugorski |
|
|
99 |
The Role of miRNAs in the Regulation of Pancreatic Cancer Stem Cells Sabrina Bimonte, Antonio Barbieri, and Francesco Izzo |
|
|
100 |
The role of miRNAs in the transcriptional program and aggressive tumor phenotype associated with hypoxia and lactic acidosis in cervical cancer Heidi Lyng, Marte Jonsson, Anja Nilsen, Malin Forsberg, Gunnar Kristensen, and Cathinka Julin |
|
|
101 |
The role of podoplanin expressed cancer-associated fibroblasts on the progression of breast cancer Jarosław Suchański, Maciej Zacharski, Piotr Dzięgiel, and Maciej Ugorski |
|
|
102 |
The role of Prolactin-Induced Protein (PIP) in apoptosis of breast cancer cells induced by doxorubicin Anna Urbaniak, Jaroslaw Suchanski, Piotr Dziegiel, and Maciej Ugorski |
|
|
103 |
The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo Antonio Barbieri, Sabrina Bimonte, Giuseppe Palma, Antonio Luciano, Domenica Rea, Giosue Scognamiglio, Sisto Perdonà, Silvia Zappavigna, Paola Stiuso, Michele Caraglia, and Claudio Arra |
|
|
105 |
Immunogenic Cell Death induction in melanoma cells: a valuable therapeutic approach in both wild type and oncogenic BRAF cells Paola Giglio, Mara Gagliardi, Mauro Piacentini, and Marco Corazzari
|
|